周恬
ZHOU Tian

• 1:贵州医科大学临床医学院

摘要(Abstract)：

目的:分析基底细胞样型乳腺癌(BLBC)癌灶组织中拓扑异构酶α(TOPOIIα)的表达及意义。方法:88例BLBC导管浸润癌患者作为观察组,同期非基底细胞样型导管浸润癌患者76例作为对照组,采用免疫组织化学方法检测两组患者癌灶组织中TOPOIIα的表达,分析其与BLBC病理特征的关系。结果:观察组TOPOIIα表达阳性率明显高于对照组,差异有统计学意义(P<0.05);BLBC癌灶组织中TOPOIIα表达与淋巴结转移、临床分期有关,差异有统计学意义(P<0.05);与年龄、民族、肿瘤大小、肿瘤组织学分级及临床分期无关,差异无统计学意义(P>0.05)。结论:癌灶组织中TOPOIIα阳性表达与BLBC发生、发展有关。
Objective: To discuss the expression of topoisomerase-α(TOPOII-α) and its clinical significance in cancer tissue of basal-like breast carcinoma( BLBC) patients. Methods: Eighty-eight patients with BLBC were selected as observation group,76 patients with invasive ductal carcinoma of non-basal-like subtype served as control group. Immunohistochemical method was used to detect the expression of TOPOII-α in cancer tissue of all patients,and its relationship with BLBC pathological characteristics and prognosis was analyzed. Results: Compared with control group,the positive rate of TOPOII-α expression was significantly higher in observation group and the differences were statistically significant( P < 0. 05). TOPOII-α expression in cancer tissue of BLBC was significantly associated with lymph node metastasis,clinical stage( P < 0. 05) while TOPOII-α expression in cancer tissue of BLBC has nothing to do with age,ethnicity and tumor size( P > 0. 05). Conclusions: TOPOII-α expression in cancer tissue of BLBC may be associated with BLBC occurrence,development,invasion and metastasis,which can be used as one effective judgment index of BLBC patient prognosis.

关键词(KeyWords)： 乳腺肿瘤;癌,基底细胞;拓扑异构酶;免疫组织化学
breast neoplasms;carcinoma,basal cell;topoisomerase;immunohistochemistry

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 周恬
ZHOU Tian

DOI: 10.19367/j.cnki.1000-2707.2015.08.016

参考文献(References)：

• [1]Perou C M Pemu CM,Sorlie T,Eisen MB,et al.Molecular portrait of human breast.tumors[J].Nature,2012(406):747-752.
• [2]Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clnicalcharacterization of the basal like subtype of iii vasive breast carcinoma[J].Clin Cancer Res,2011(10):5367-5374.
• [3]Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer subtypes,and survical in the Carolina breast cancer study[J].JAMA,2006(21):2492-2502.
• [4]Jarvinen TA,Tanner M,Rantanen V,et al.Amplification and deletion of topoisomeraseⅡalphah associate with Er B2 amplification and affect sensitivity to topoisomeraseⅡalphah inhibitor dosorubicin doxorubicin in breast cancer[J].Am J Pathol,2010(3):839-847.
• [5]Sorile T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor sumor subclasses with clinical implications[J].Proc Nat Acad Sci USA,2010(69):10869-10874.
• [6]Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clnicalcharacterization of the basal like subtype of iii vasive breast carcinoma[J].Clin Cancer Res,2004(10):5367-5374.
• [7]MIN Li-shan,CHEN Ying-rong,MA Zhi-hong,et al.Expression and clinical significance of midkine in breast carcinomas with different immunohistochemical profiling[J].Current Immunology,2012(5):381-386.
• [8]Bauer K R,Brown M,CressR D,et al.Descriptive analysis of estrogen receptor(ER)Negative,progesterone receptor(PR)negative,and HER-2 negative invasive breast cancer,the socalled triple negative phenotype:a population based study from the California cancer Regaistry[J].Cancer,2007(109):1721-1728.
• [9]Sng JH,Heaton VJ,Bell M,et al.Molecular cloning and characterization of the human topoisomeraseⅡalpha andⅡbeta genes:Evidence for isoform evolution through gene duplication[J].Biochim Biophys Acta,2009(1444):395-406.
• [10]孟辉,李文才,王留兴,等.拓扑异构酶Ⅱα表达与乳腺癌患者生存的相关性[J].中华肿瘤杂志,2011(5):363-366.

文章评论(Comment)：